The rationale behind the trial rests on a well-documented but often overlooked problem in psychiatric medicine. People with schizophrenia die substantially earlier than the general population, and much of that gap is driven by cardiovascular and metabolic disease. Alongside these mortality risks, patients frequently experience accelerated declines in mobility, balance, and muscle function that mirror patterns normally seen in much older adults. Antipsychotic medications, sedentary lifestyles, institutional living, and the symptoms of the illness itself all contribute. Poor physical performance, in turn, is tightly linked to disability, falls, loss of independence, and reduced quality of life. Yet psychiatric inpatient care has historically focused almost exclusively on symptom control, leaving physical deterioration largely unaddressed. The Chinese team set out to test whether a systematic exercise prescription, embedded within routine inpatient care, could shift that trajectory.

The intervention was designed according to the FITT framework, which specifies the frequency, intensity, time, and type of exercise, and combined several training modalities into a single multicomponent program. Participants in the exercise group trained over twelve weeks, with sessions blending aerobic conditioning, resistance work, and balance training, and with intensity calibrated using ratings of perceived exertion and heart rate monitoring rather than fixed workloads. This individualized calibration matters: patients with schizophrenia vary widely in baseline fitness, medication burden, and motivation, and a program that is too demanding risks dropout while one that is too gentle produces no adaptation. The comparison group continued with treatment as usual, receiving standard psychiatric care without a structured exercise component. The trial was prospectively registered with the Chinese Clinical Trial Registry on 15 July 2025, and ethical approval was obtained from the Shandong Mental Health Center, with written informed consent from all participants.

The primary outcome was the Short Physical Performance Battery, or SPPB, a widely validated composite measure that sums performance on three tasks: standing balance, gait speed over four meters, and the time required to rise from a chair and sit down five times. Because each component captures a different dimension of lower-body function, the SPPB provides a sensitive snapshot of overall physical capacity and is a strong predictor of future disability in older adults. Secondary outcomes included cardiorespiratory endurance measured by the six-minute walking test, dynamic balance and mobility captured by the Timed Up and Go Test, muscle strength assessed through handgrip dynamometry and sit-to-stand tests, and muscle quantity estimated through appendicular skeletal muscle mass and its index, which reflect the amount of muscle in the arms and legs relative to body size.

The statistical approach was deliberately conservative. The primary analysis used a modified intention-to-treat framework, including the 93 of 102 randomized participants who had usable outcome data, while a sensitivity analysis in the full intention-to-treat population of all 102 participants employed multiple imputation to handle missing values. This dual strategy guards against a common pitfall in exercise trials, where participants who drop out are often those who were struggling most, which can inflate apparent benefits. By checking whether the findings survive under the most inclusive assumptions, the researchers provided a stronger test of whether the exercise program genuinely worked rather than merely appearing to work among the most compliant participants.

The headline result was a statistically significant improvement in overall physical function. In the modified intention-to-treat analysis, the exercise group outperformed the control group on the SPPB total score by a mean difference of 1.16 points, with a 95 percent confidence interval of 0.57 to 1.74 and a p value below 0.001. To put that number in context, changes of roughly half a point to one point on the SPPB are considered clinically meaningful in older populations, and a gain of more than one point over just twelve weeks represents a substantial functional shift. The exercise group also performed significantly better on the Timed Up and Go Test, completing the task 1.37 seconds faster on average, with a confidence interval of −2.33 to −0.42 seconds and a p value of 0.005. Faster times on this test reflect better integrated mobility, requiring the participant to stand from a chair, walk three meters, turn, return, and sit down again, all of which depend on strength, balance, and coordination working together.

The sensitivity analysis in the full intention-to-treat population largely reinforced these conclusions. Significant group-by-time interactions were confirmed for the SPPB, the Timed Up and Go Test, and handgrip strength, all with p values below 0.001, indicating that the improvements over time genuinely differed between the two groups rather than arising by chance. Handgrip strength, however, showed a nuance worth noting: although the interaction was significant, the between-group difference after the intervention itself did not reach statistical significance, with a p value of 0.058, just above the conventional threshold. This suggests that grip strength may have been trending toward improvement but that twelve weeks, or the sample size available, was not quite sufficient to establish a firm between-group effect on that specific measure.

Not every outcome survived the stricter analysis, and the authors were candid about these limits. The significant interaction effects for the six-minute walking test, appendicular skeletal muscle mass, and the appendicular skeletal muscle mass index observed in the modified intention-to-treat analysis were not confirmed in the intention-to-treat sensitivity analysis, with all p values exceeding 0.05. In practical terms, the effects on cardiorespiratory endurance, handgrip strength, and muscle mass remain inconclusive. This pattern is physiologically plausible. Balance and mobility are neural as much as muscular qualities, driven by coordination, motor learning, and confidence, all of which can improve relatively quickly with task-specific practice. Building aerobic capacity and adding actual muscle tissue, by contrast, typically demands longer training durations, higher progressive loads, and adequate nutritional support, factors that are harder to control in an inpatient psychiatric population where appetite, metabolism, and medication effects complicate the picture.

For the researchers, the consistent gains in overall physical function, balance, and mobility are enough to support a concrete recommendation: multicomponent exercise deserves a place in routine psychiatric inpatient care. The trial’s setting is central to this argument. The program was delivered within a mental health facility to inpatients, a group that is often excluded from community exercise studies precisely because of symptom burden, medication side effects, and logistical barriers. Demonstrating feasibility and efficacy in this real-world context suggests that the model could be translated to other psychiatric hospitals without extraordinary resources, using staff-supervised sessions and simple monitoring tools such as perceived exertion scales rather than laboratory equipment.

The broader significance of the trial extends beyond schizophrenia itself. It joins a growing body of work showing that structured physical activity is a legitimate medical intervention, with measurable, quantifiable effects on function that rival those of pharmacological treatments for other conditions. For a patient population whose life expectancy gap is driven largely by preventable physical disease, an intervention that improves the physical capacity needed to stay active, avoid falls, and maintain independence addresses a critical gap in care. The open questions that remain, including whether longer programs can strengthen endurance and muscle mass, whether benefits persist after discharge, and whether improved physical function feeds back into psychiatric symptoms and quality of life, now define the next frontier for this line of research. What the current evidence establishes is the essential first step: in middle-aged and older patients with schizophrenia, twelve weeks of the right exercise, properly dosed and supervised, reliably makes the body work better.

Subject of Research: Effects of a 12-week multicomponent exercise program on physical function in middle-aged and older patients with schizophrenia

Article Title: Effects of 12-week multicomponent exercise on physical function in middle-aged and older patients with schizophrenia: a randomized controlled trial

Article References: Wang, M., Song, X., Wang, B., Zhang, K., Hao, L., Wang, R., Shi, Z., Cheng, Y., Shi, L., Li, N., & Su, L. (2026). Effects of 12-week multicomponent exercise on physical function in middle-aged and older patients with schizophrenia: a randomized controlled trial. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08645-2

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08645-2

Keywords: schizophrenia, multicomponent exercise, physical function, randomized controlled trial, Short Physical Performance Battery, Timed Up and Go Test, balance, mobility, handgrip strength, muscle mass, psychiatric inpatients, BMC Psychiatry